Calumet (CLMT) Gets 82% Price Target Hike to $60 by H.C. Wainwright
NEW YORK, March 31 -
What Actually Happened
H.C. Wainwright didn't just nudge its Calumet, Inc. (CLMT) price target. it effectively declared a new company. The firm raised its target to $60 from $33, an 82% increase, after the specialty refiner pulled off something that reads less like incremental improvement and more like financial resurrection: a $115mn swing in cash from operations, landing at $108.9mn in 2025 after posting negative $6.4mn in 2024. Going from burning cash to generating nine figures of it in twelve months is the kind of inflection that forces analysts to rebuild their models from scratch. and that's precisely the repricing opportunity Wainwright is flagging.
The Setup
Think of Calumet as two businesses duct-taped together. There's the legacy specialty refining operation. niche, profitable, unglamorous. Then there's Montana Renewables, the subsidiary building out MaxSAF 150, a sustainable aviation fuel expansion scheduled for Q2 2026. That project targets a market with a structural supply deficit: domestic SAF production can't keep pace with airline demand as regulators tighten blending mandates. It's the rare situation where the customer is being legally compelled to buy your product. Meanwhile, crude oil near $95/barrel has widened crack spreads and supercharged margins in the conventional business, anchoring the cash generation case behind Wainwright's revised target. Multiple analysts have raised price targets on CLMT in recent weeks. a sharp reversal from mid-2024, when the stock languished below $20 and operating losses and elevated leverage defined the narrative. At $35.04, CLMT trades at a 42% discount to the new Wainwright target. but at 103.1x forward P/E against $4.1bn in TTM revenue, the market is already pricing in a future that hasn't arrived yet.
The Catch
A 103x forward P/E is not a valuation. it's a bet. And the single variable that determines whether it pays off is the MaxSAF 150 completion date and first production figures out of Montana Renewables, expected Q2 2026. An on-time startup would confirm Montana Renewables has completed its metamorphosis from capital sink to cash contributor and would likely trigger another round of analyst upgrades. But here's the uncomfortable math: at this multiple, even a one-quarter schedule slip would revive the execution risk concerns that battered the stock through 2023 and 2024. Two consecutive years of negative operating cash flow preceded the 2025 turnaround. which means investors should scrutinize Q1 2026 operating cash flow, due before the expansion opens, for confirmation that the improvement was structural rather than a product of one-time items. At 103.1x forward P/E, the stock has priced in perfection and left no margin for a stumble on either the cash flow trajectory or the expansion timeline.
Bottom Line
Calumet's cash flow inflection is real and the SAF market tailwind is structural. But there's a reason the stock still sits 42% below Wainwright's target: the market wants proof that Montana Renewables can produce fuel, not just consume capital. Q2 2026 is the verdict. Until MaxSAF 150 ships product, this is a show-me story trading at a trust-me multiple.
Calumet does not yet have a Basis Report analysis on file. generate a full breakdown at /stock/clmt.
Basis Report does not hold positions in securities discussed. This is not investment advice.